MILAN--(BUSINESS WIRE)-- Tineco updates its ecosystem with a new model: the FLOOR ONE Stretch S6. This floor washer has a unique peculiarity: it is able to bend 180° degrees, so as to reach any surface, whether under furniture or a hidden corner of the house.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603868347/en/
TINECO FLOOR ONE Stretch S6 (Photo: Business Wire)
Equipped with the latest... (continue reading...)
Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience
CAMBRIDGE, England--(BUSINESS WIRE)-- Mursla Bio is pleased to announce the publication of its latest peer-reviewed paper in iScience, an interdisciplinary journal of the esteemed Cell Press. The paper showcases Mursla Bio’s breakthrough technology for the analysis of extracellular vesicles (EV) sub-types within biofluids such as blood. EVs are important actors in... (continue reading...)
NEW YORK--(BUSINESS WIRE)-- Aqara, a global leader and pioneer in IoT, announced the debut of its Amazon brand store in the Netherlands. This expansion to the Amazon marketplace marks a significant step in increasing the accessibility of Aqara's smart home lineup to Dutch consumers.
Since opening its first European Amazon brand store in the UK in 2021, Aqara has consistently broadened its reach in the e-commerce marketplace in this region, now including France,... (continue reading...)
Initiative supported by a broader Accenture and Kraken ecosystem partnership focused on helping utilities transform customer experience
LONDON--(BUSINESS WIRE)-- Accenture (NYSE: ACN) and Kraken Technologies are helping EDF’s UK retail business accelerate the migration of customers to its new platform, enabling them to effectively manage their energy use and cost.
EDF has migrated over five million meter points in the UK onto Kraken, the technology behind... (continue reading...)
DUBLIN--(BUSINESS WIRE)-- Invicara will unveil digitaltwin-factory, an open-source program, at the Digital Construction Week in ExCeL London, 5th & 6th June. Enterprise innovation teams, and software solution providers can now join the digitaltwin-factory community, access free to use open source digital twin building blocks, and create their own commercial applications.
Invicara’s decision to embrace open-source software, is aimed at accelerating innovation,... (continue reading...)
More Business Wire
View Older Stories-
Veolia Launches a New Employee Stock Ownership Plan Offered to nearly 190,000 Group employees
-
Nidec Announces the Status of Own Share Repurchase
-
Wedding Season Is Open: A Radiant Bride and a Wedding to Remember with Quanta's Laser Skincare!
-
Ferguson Files Form 8-K
-
Modern Card Issuing Platforms to Issue 35% of All Payment Cards by 2029, as Banks Begin to Compete on User Experience
-
AM Best to Host Insurance Market Briefing in Amsterdam to Review Challenges and Emerging Issues Facing European Carriers
-
Igloo Coolers Makes Its First-Ever Debut in the Active Cooling Category at Outdoor by ISPO
-
Thermo Fisher Scientific Opens New GMP-certified Ultra-cold Facility in the EU to Accelerate Advanced Therapies Development
-
Discover® Global Network Study Shows 85% of Consumers are Less Likely to Interact with a Business Due to a Poor Payment Experience
-
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
-
Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors
-
Axway Announces the Signing of Binding Agreements for the Acquisition of Sopra Banking Software
-
Sopra Steria: A Significant Milestone Achieved in the Group’s Strategy to Refocus Its Activities on Digital Services and Solutions
-
“MOURI Tech” Expands Global Footprint with Acquisition of “Versant Systems”, Strengthening Presence in APAC Region
-
GenSight Biologics Appoints William Monteith to its Board of Directors
-
Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
-
Triumph Motorcycle Dealers Ranked First in Industry Study for Providing Quick and Easy Service Appointments
-
Appointment of Director to Woodside Board
-
Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
-
WEBTOON Entertainment Announces Public Filing of Registration Statement for Proposed Initial Public Offering
-
Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
-
New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse
-
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
-
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated
-
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
-
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
-
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
-
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
-
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
-
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
-
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
-
June Joy at Juicy Stakes Casino
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
-
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
-
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma